Selectivity of cholinesterase inhibition: Clinical implications for the treatment of Alzheimer's disease

CNS Drugs

Volumn 12, Issue 4, 1999, Pages 307-323

  Weinstock, Marta ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; RIVASTIGMINE;

ALZHEIMER DISEASE; AMNESIA; BRAIN BLOOD FLOW; BRAIN MICROCIRCULATION; CHOLINERGIC TRANSMISSION; COGNITION; DAILY LIFE ACTIVITY; DRUG STRUCTURE; FOREBRAIN; GLUCOSE METABOLISM; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

EID: 0032741056     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912040-00005     Document Type: Review

References (110)

1. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9
2. Hoyer S. Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases. Mol Chem Neuropathol 1992; 16: 207-24
3. Swedlow R, Marcus DL, Landman J, et al. Brain glucose metabolism in Alzheimer's disease. Am J Med Sci 1994; 308: 141-4
4. De la Torre JC. Impaired brain microcirculation may trigger Alzeimer's disease. Neurosci Biobehav Revs 1994; 18: 397-401
5. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylchofinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909-18
6. Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog Brain Res 1993; 98: 431-8
7. Weinstock M, Razin M, Chorev M, et al. Pharmacological evaluation of phenyl-carbamates as CNS selective acetylcholinesterase inhibitors. J Neural Transm 1994; s43: 219-25
8. Bryson HM, Benfield P. Donepezil. Drugs Aging 1997; 10: 234-9
9. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Arch Int Med 1995; 155: 1766-72
10. Thal LJ, Fergusen JM, Mintzer J, et al. A 24-week randomized trial of controlled release physostigmine in patients with Alzheimer's disease. Neurology 1999; 52: 1146-52
11. Canal N, Imbimbo BP. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1996; 60: 218-28
12. Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatric Psychopharmacol 1998; 1: 55-65
13. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
14. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998; 50: 1214-21
15. Quin DM, Selwood T, Pryor AN, et al. Cryptic catalysis and cholinesterase function. In: Shafferman A, Velan B, editors. Multidisciplinary approaches to cholinesterase function. New York (NY): Plenum Press, 1992: 141-8
16. Appleyard ME. Secreted acetylcholinesterase: non-classical aspects of a classical enzyme. Trends Neurosci 1992; 15 (12): 485-90
17. Small DH. Non-cholinergic actions of acetylcholinesterases: proteases regulating cell growth and development. Trends Biochem Sci 1990; 15 (6): 213-6
18. Ehrlich G, Viegas-Pequignot E, Ginzberg D, et al. Mapping the human acetycholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries. Genomics 1992; 13: 1192-7
19. Massoulic J, Pezzementi L, Bon S, et al. Molecular and cellular biology of cholinesterases. Progr Neurobiol 1993; 41: 31-91
20. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986; 47 (1); 263-77
21. Siek GC, Katz LS, Fishman EB, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry 1990; 27: 573-80
22. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872-9
23. Changeux J-P. Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs. Mol Pharmacol 1966; 2: 369-92
24. Cullumbine H. Actions at autonomic effector sites. In: Eichler O, Farah A, Koelle GB, editors. Handbuch der experimentellen pharmakologie: cholinesterases and anti-cholinesterase agents. Berlin: Springer-Verlag, 1963: 515-6
25. Harel M, Sussman JL, Krejei F, et al. Conversion of acetylcholinesterase to butyryl-cholinesterase. Modeling and mutagenesis. Proc Natl Acad Sci U S A 1992; 89 (22): 10827-31
26. Snape MF, Misra A, Murray TK, et al. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology 1999; 38: 181-93
27. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74: 225-41
28. Fulton B, Benfield P. Galanthamine. Drugs Aging 1996; 9: 60-5
29. Kryger G, Silman I, Sussman JL. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo California. J Physiol Paris 1998; 92: 191-4
30. Doody RS, Clinical profile of donepezil in the treatment of Alzheimer's disease. Gerontology 1999; 45: 23-32
31. Knapp MJ, Gracon SI, Davis CS, et al. Efficacy and safety of high-dose tacrine: a 30-week evaluation. Alz Dis Assoc Disord 1994; 8: s22-s31
32. Weinstock M. Possible role of the cholinergic system and disease models. J Neural Transm 1997; Suppl. 49: 93-102
33. Thomsen T, Kaden B, Fischer JP, et al. Inhibition of acetylcholinesterase activity in human brain tissue and crythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem 1991; 29: 487-92
34. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
35. Farlow MR, Hake AM. Mechanism of action and metabolism of acetylcholinesterase inhibitors: implications for treatment. Int J Ger Psychopharmacol 1998; 1 Suppl. 1: s2-s6
36. Enz A, Florsheim P. Cholinesterase inhibitors: an overview of their mechanism of action. In: Becker R, Giacobini F, editors, Alzheimer's disease. From molecular biology to therapy. Boston (MA); Birkhauser, 1996: 211-5
37. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998; 97: 244-50
38. Sramek JJ, Block GA, Reines SA, et al. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1995; 56 (5): 319-26
39. Organe N, Giacobini E, Messamore E, Preferential inhibition of acetylcholinesterase forms in rat brain. Neurochem Res 1992; 17: 485-95
40. Burner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32 (1): 70-7
41. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997; 11: 490-6
42. Summers WK, Majovski LV, Marsh CM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986; 315: 1241-5
43. McNally WP, Pool WF, Sinz MW, et al. Distribution of tacrine and metabolites in rat brain and plasma after single and multiple-dose regimens: evidence for the accumulation of tacrine in brain tissue. Drug Metab Dispos 1996; 24: 628-33
44. Weinstock M, Kay G, Razin M, et al. Selective inhibition of acetylcholinesterase and acetylcholine turnover in the cortex and hippocampus. In: Cohen S, Sokolovsky M, editors. Muscarinic cholinergic mechanisms. Tel Aviv: Freund Publishing House, 1987
45. Kaufer DI, Catt KE, Lopez OL, et al. Dementia with Lewy bodies: response of delirium-like features to donepezil. Neurology 1998; 51 (5): 1512
46. Burstyn SA, Harker LA. Control of platelet production. Clin Haematol 1983; 12: 3-27
47. Imbimbo BP, Martelli P, Troetel WM, et al. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology 1999; 52: 700-8
48. Zemlan FP, Keys M, Richter RW, et al. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. Life Sci 1996; 58: 1823-32
49. Brufani M, Marta M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysotigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 1986; 157: 115-20
50. Anand R, Gharabawi G. Clinical development of Exelon™(ENA-713): the ADENA programme. J Drug Dev Clin Pract 1996; 8: 9-14
51. Nakamura S, Takemura M, Suenaga T, et al. Occurrence of acetylcholinesterase activity closely associated with amyloid β/A4 protein is not correlated with acetylcholinesterase-positive fiber density in amygdala of Alzheimer's disease. Acta Neuropathol 1992; 84: 425-32
52. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyliod-beta-peptides into Alzneimer's fibrils; possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91
53. Mesulam M-M, Geula C, Moran MA. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroamnoacridine on plaques and tangles. Ann Neurol 1987; 22: 683-91
54. Chong YH, Su Y-H. Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci 1996; 59: 545-57
55. Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta (25-35) in rat PC 12 cells. Neuroreport 1998; 9: 1519-22
56. Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. In: Becker R, Giacobini H, editors. Alzheimer's disease. From molecular biology to therapy. Boston (MA): Birkhauser, 1996: 187-204
57. Kowall NW, McKee AC, Yankner BA, et al. In vivo neurotoxicity of β-amyloid β(1-40) and the β(25-35) fragment. Neurobiol Aging 1992; 13: 537-42
58. Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally-administered β-amyloid peptides involves cholinergic dysfunction. Brain Res 1996; 706: 181-93
59. 11C] methionine accumulation in probable Alzheimer's disease using positron emission tomography. J Cereb Blood Flow Metab 1996; 16: 309-408
60. Simpson IA, Koteswara RC, Davies-Hill T, et al. Decreased concentraitions of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994; 35: 546-51
61. Horwood N, Davies DC. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Archiv 1994; 425: 69-72
62. Kalaria RN, Hank SI. Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease. Prog Clin Bio Res 1989; 317: 415-21
63. Kiyosawa M, Baron J-C, Hamel E, et al. Time course of effects of unilateral lesions of the nucleus basalis of Meynert on glucose utilisation by the cerebral cortex. Brain 1989; 112: 435-55
64. Sato A, Sato Y. Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Neurosci Res 1992; 14: 242-74
65. Abe K, Tanzi RE, Kogure K, Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett 1991; 125: 172-4
66. Katzman R. Alzheimer's disease. N Engl J Med 1986; 314: 964-73
67. Seremin OU, Allen K, Torres C, et al. Physostigmine enhances blood flow-metabolism ratio in neocortex. Neuropsychopharmacol 1988; 1: 297-303
68. Seremin OU, Seremin AME, Heuser D, et al. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats. J Cereb Blood Flow Metab 1993; 13: 702-11
69. Peruzzi P, Borredon J, Seylaz J, et al. Tacrine overcomnensates for the decreased blood flow induced by basal forebrain lesion in the rat. Neuroreport 1996; 8: 103-8
70. Tsukada H, Kakiuchi T, Ando I, et al. Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys. J Pharmacol Exptl Ther 1997; 281: 1408-14
71. Ebmeier KB, Hunter R, Curran SM, et al. Effects of a single dose of me aceylcholinesterase inhibitor velnacrine on recognition memory and regional blood flow in Alzheimer's dis case. Psychopharmacol 1992; 108: 103-9
72. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow. Dementia 1993; 4: 32-42
73. Harkins SW, Taylor JR, Mattay V, et al. Tacrine treatment in Alzheimer's disease enhances cerebral blood flow and mental status and decreases caregiver suffering. Ann N Y Acad Sci 1997; 826: 472-4
74. Tanaka K, Mizukawa K, Ogawa N, et al. Post-ischemic administration of the acetyl-cholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus. Neurochem Res 1995; 20: 663-7
75. Tanaka K, Ogawa N, Mizukawa K, et al, Aceylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochem Res 1994; 19: 117-22
76. Sadoshima S, Ibayashi S, Fujii K, et al. Inhibition of acetylcho linesterase modulates the autoregulation of cerebral blood flow and attenuates ischemic brain metabolism in hypertensive rats. J Cereb Blood Flow Metab 1995; 15: 845-51
77. Gentleman SM, Graham DI, Robert G.W. Molecular pathology of head trauma: Altered βAPP metabolism and the aetiology of Alzheimer's disease. Prog Brain Res 1993; 96: 237-46
78. Then Y, Shohami E, Bass R, et al. Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat. Brain Res 1998; 784: 18-24
79. Chen Y, Shohami E, Constanini S, et al. Rivastigmine, a brain-selective acetyl-cholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. J Neurotrauma 1998: 15; 231-7
80. Zauner A, Bullock R. The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review, J Neurotrauma 1995; 12: 547-54
81. Taverni JP, Seliger G, Lichtman SW. Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj 1998; 12: 77-80
82. Bassant MH, Jazat-Poindessous F, Lamour Y. Metabolic response to tacrine (THA) and physostigmine in the aged rat brain. J Cerch Blood Flow Metab 1995; 15: 1093-102
83. Bassant MH, Jazat-Poindessous F, Lamour Y, Effect of metri fonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cereb Blood Flow Metab 1996; 16: 1014-25
84. Rickkenen Jr P, Aaltonen M, Sirvio J, et al. Tetrahydroam inoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits. Physiol Behav 1991; 49: 1147-52
85. Rickkenen Jr P. Schmidt B, Stefanski R, et al. Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 1996; 309: 121-30
86. Duelli R, Schrock G, Kuschinsky W, et al. Intraccrebroventrieular injection of streptozotocin induces discrete local changes in cerebral glucose utilisation in rats. Int J Dev Neurosci 1994; 12: 737-43
87. Weinstock M, Increase in cerebral blood flow and glucose utilization in beneficial effect of a cholinesterase inhibitor ENA713, in Alzheimer's disease, In: Fisher A, Hanin I, Yoshida M, editors. Progress in Alzheimer's and Parkinson's diseases New York and London: Plenum Press, 1998: 587-95. (Adv Behav Biol: 49)
88. Mohs RC, Ferris SH. Measuring response to treatment in Alzheimer's disease: what constitutes meaningful change? Int J Geriatric Psychopharmacol 1598; 1 Suppl, 1: S7-S14
89. Spencer CM, Nable S, Rivastigmine. A review of its use in Alzeimer's disease. Drugs Aging 1998; 13: 391-411
90. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safely of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318 (7184): 633-8
91. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open-label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75
92. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44
93. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999; 45 Suppl. 1: 15-22
94. Thomson T, Kewitz H, Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46: 1553-8
95. Riemann D, Gann H, Dressing H, et al. Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. Psychiatr Res 1994; 51: 253-67
96. Sano M, Bell K, Marder K, et al. Safety and efficacy of oral physostigmine in the treatment of Alzheimer's disease. Clin Neuropharmacol 1993; 16: 61-9
97. Cutler NR, Jhee SS, Cyrus P, et al. Safety and tolerability of metrifonate in patents with Alzheimer's disease: results of maximum tolerated dose study. Life Sci 1998; 62: 1433-41
98. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of butyrylcholinesterase in the human neocortex during development und degeneration of the cortical cholinergic system. J Neurochem 1987; 48 (6): 1687-92
99. Cutler NR, Sramek JJ. Tolerability profiles of AChEIs: a critical component of care for Alzheimer's disease patients. Int J Geriatric Psychopharmacol 1998; 1 Suppl. 1: S20-S25
100. Stern Y, Sano M, Mayeux R. Effects of oral physostigmine in Alzheimer's disease. Ann Neurol 1987; 22: 306-10
101. Thal LJ, Fuld PA, Masur DM, et al. Oral physostigmine and lecithin improve memory in Alzheimer's disease. Ann Neurol 1983; 13: 491-6
102. Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199-206
103. 2 receptors. Brain Res 1996; 726: 207-12
104. Braida D, Paladini E, Griffini P, et al. An inverted U shaped curve for heptyl-physostigmine on radial maze performance in rats: comparison with other cholinesternse inhibitors. Eur J Pharmacol 1996; 302: 13-20
105. Yoshida S, Suzuki N. Antiammnestic and cholinomimetic side effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats. Eur J Phatmacol 1993; 150: 117-24
106. Wanibuchi F, Nishida T, Yamashita H, et al. Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in vivo pharmacological studies. Eur J Phramacol 1994; 265: 151-8
107. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998; 60: 377-86
108. Flood JF, Smith GE, Cherkin A. Memory retention: potentiation of cholinergic drug combinations in mice. Neurobiol Aging 1983; 4: 37-43
109. Cutler NR, Sramek JJ, Murphy MF, et al. Alzheimer's patients should he included in phase I clinical trials to evaluate compounds for Alzheimer's disease. J Geriatr Psychiatry Neurol 1992; 5: 192-4
110. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon™ (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996; 8: 1-8